MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement

cafead

Administrator
Staff member
  • cafead   Apr 15, 2024 at 11:43: AM
via Lyon, France-based MaaT Pharma has announced positive 18-month data for its lead candidate MaaT013 showing an overall survival advantage in acute graft versus host disease (aGvHD).

article source